---
document_datetime: 2025-12-02 05:34:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva.html
document_name: covid-19-vaccine-inactivated-adjuvanted-valneva.html
version: success
processing_time: 0.12306
conversion_datetime: 2025-12-24 02:14:57.033787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# COVID-19 Vaccine (inactivated, adjuvanted) Valneva

[RSS](/en/individual-human-medicine.xml/67596)

##### Withdrawn

This medicine's authorisation has been withdrawn

COVID-19 vaccine (inactivated, adjuvanted, adsorbed) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Safety updates](#safety-updates)
- [News on COVID-19 Vaccine (inactivated, adjuvanted) Valneva](#news-on)
- [More information on COVID-19 Vaccine (inactivated, adjuvanted) Valneva](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 12 October 2023, the European Commission withdrew the marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva (SARS-CoV-2 virus, strain Wuhan hCoV-19/Italy/INMI1- isl/2020, inactivated) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Valneva Austria GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva was granted marketing authorisation in the EU on 24 June 2022 for active immunisation against coronavirus disease 2019 (COVID-19). The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for COVID-19 Vaccine (inactivated, adjuvanted) Valneva is updated to indicate that the marketing authorisation is no longer valid.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : EPAR - Medicine overview

English (EN) (276.06 KB - PDF)

**First published:** 27/06/2023

**Last updated:** 01/12/2023

[View](/en/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-461)

български (BG) (412.12 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/bg/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_bg.pdf)

español (ES) (296.05 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/es/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_es.pdf)

čeština (CS) (353.49 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/cs/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_cs.pdf)

dansk (DA) (280.97 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/da/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_da.pdf)

Deutsch (DE) (314.28 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/de/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_de.pdf)

eesti keel (ET) (273.24 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/et/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (416.76 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/el/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_el.pdf)

français (FR) (301.09 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/fr/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (340.66 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/hr/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_hr.pdf)

italiano (IT) (285.18 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/it/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (359.53 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/lv/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (343.51 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/lt/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_lt.pdf)

magyar (HU) (327.46 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/hu/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_hu.pdf)

Malti (MT) (397.24 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/mt/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (302.98 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/nl/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_nl.pdf)

polski (PL) (353.81 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/pl/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_pl.pdf)

português (PT) (293.01 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/pt/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_pt.pdf)

română (RO) (360.97 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/ro/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (371.58 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/sk/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (329.43 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/sl/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_sl.pdf)

Suomi (FI) (277.49 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/fi/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_fi.pdf)

svenska (SV) (281.18 KB - PDF)

**First published:**

27/06/2023

**Last updated:**

01/12/2023

[View](/sv/documents/overview/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-medicine-overview_sv.pdf)

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : EPAR - Risk-management-plan

English (EN) (1.36 MB - PDF)

**First published:** 23/06/2022

**Last updated:** 01/07/2022

[View](/en/documents/rmp/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-risk-management-plan_en.pdf)

## Product information

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : EPAR - Product information

English (EN) (1.03 MB - PDF)

**First published:** 23/06/2022

**Last updated:** 01/12/2023

[View](/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_en.pdf)

[Other languages (22)](#file-language-dropdown-691)

български (BG) (1.39 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/bg/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_bg.pdf)

español (ES) (1.1 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/es/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_es.pdf)

čeština (CS) (1.19 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/cs/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_cs.pdf)

dansk (DA) (1.01 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/da/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_da.pdf)

Deutsch (DE) (1.08 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/de/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_de.pdf)

eesti keel (ET) (974.37 KB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/et/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_et.pdf)

ελληνικά (EL) (1.46 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/el/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_el.pdf)

français (FR) (1.04 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/fr/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_fr.pdf)

hrvatski (HR) (1.15 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/hr/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_hr.pdf)

italiano (IT) (1.09 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/it/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.27 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/lv/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/lt/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_lt.pdf)

magyar (HU) (1.2 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/hu/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_hu.pdf)

Nederlands (NL) (1.08 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/nl/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_nl.pdf)

norsk (NO) (991.74 KB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/no/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_no.pdf)

polski (PL) (1.27 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/pl/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_pl.pdf)

português (PT) (1.02 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/pt/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_pt.pdf)

română (RO) (1.3 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/ro/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_ro.pdf)

slovenčina (SK) (1.21 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/sk/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_sk.pdf)

slovenščina (SL) (1.18 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/sl/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_sl.pdf)

Suomi (FI) (1.03 MB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/fi/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_fi.pdf)

svenska (SV) (982.29 KB - PDF)

**First published:**

23/06/2022

**Last updated:**

01/12/2023

[View](/sv/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0004 12/10/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : EPAR - All authorised presentations

English (EN) (86.74 KB - PDF)

**First published:** 01/07/2022

**Last updated:** 01/12/2023

[View](/en/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-852)

български (BG) (144.11 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/bg/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_bg.pdf)

español (ES) (121.79 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/es/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (126.11 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/cs/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (119.05 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/da/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (123.25 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/de/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (116.88 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/et/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (134.61 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/el/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_el.pdf)

français (FR) (124.6 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/fr/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (122.34 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/hr/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (131.46 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/is/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (120.11 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/it/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (123.85 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/lv/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (123.75 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/lt/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (121.79 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/hu/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (134.68 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/mt/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (120.28 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/nl/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (129.29 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/no/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_no.pdf)

polski (PL) (137.11 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/pl/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_pl.pdf)

português (PT) (124.04 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/pt/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_pt.pdf)

română (RO) (123.01 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/ro/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (125.73 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/sk/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (124.15 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/sl/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (114.96 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/fi/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (117.48 KB - PDF)

**First published:**

01/07/2022

**Last updated:**

01/12/2023

[View](/sv/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine COVID-19 Vaccine (inactivated, adjuvanted) Valneva Active substance COVID-19 vaccine (inactivated, adjuvanted, adsorbed) International non-proprietary name (INN) or common name COVID-19 vaccine (inactivated, adjuvanted, adsorbed) Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J07BX03

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

COVID-19 Vaccine (inactivated, adjuvanted) Valneva is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 to 50 years of age.

The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/006019 Marketing authorisation holder

Valneva Austria GmbH

Campus Vienna Biocenter 3 Landstrasse A-1030 Vienna Austria

Opinion adopted 23/06/2022 Marketing authorisation issued 24/06/2022 Withdrawal of marketing authorisation 12/10/2023 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (329.01 KB - PDF)

**First published:** 02/08/2022

**Last updated:** 01/12/2023

[View](/en/documents/procedural-steps-after/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : EPAR - Public assessment report

Adopted

Reference Number: EMA/627695/2022

English (EN) (8.35 MB - PDF)

**First published:** 08/07/2022

**Last updated:** 01/12/2023

[View](/en/documents/assessment-report/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for COVID-19 Vaccine (inactivated, adjuvanted) Valneva

Adopted

Reference Number: EMEA/H/C/006019

English (EN) (267.38 KB - PDF)

**First published:** 23/06/2022

**Last updated:** 01/12/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-inactivated-adjuvanted-valneva_en.pdf)

#### Safety updates

COVID-19 vaccines - Safety update: 14 July 2022

Adopted

Reference Number: Rev. 1

English (EN) (263.34 KB - PDF)

**First published:** 14/07/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-14-july-2022_en.pdf)

COVID-19 vaccines - Safety update: 8 September 2022

Adopted

English (EN) (257.73 KB - PDF)

**First published:** 08/09/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-september-2022_en.pdf)

COVID-19 vaccines - Safety update: 6 October 2022

Adopted

English (EN) (237.46 KB - PDF)

**First published:** 06/10/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-6-october-2022_en.pdf)

COVID-19 vaccines - Safety update: 8 December 2022

Adopted

English (EN) (239.73 KB - PDF)

**First published:** 08/12/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf)

COVID-19 vaccines - Safety update: 10 November 2022

Adopted

English (EN) (254.94 KB - PDF)

**First published:** 10/11/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf)

COVID-19 Vaccine (inactivated, adjuvanted) Valneva: Periodic safety update report assessment 28 February 2022 to 27 August 2022

Adopted

English (EN) (2.43 MB - PDF)

**First published:** 27/09/2023

**Last updated:** 01/12/2023

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-inactivated-adjuvanted-valneva-periodic-safety-update-report-assessment-28-february-2022-27-august-2022_en.pdf)

COVID-19 Vaccine (inactivated, adjuvanted) Valneva : Periodic safety update report assessment 28 August 2022 to 27 February 2023

Adopted

English (EN) (1.73 MB - PDF)

**First published:** 30/10/2023

**Last updated:** 01/12/2023

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-inactivated-adjuvanted-valneva-periodic-safety-update-report-assessment-28-august-2022-27-february-2023_en.pdf)

#### News on COVID-19 Vaccine (inactivated, adjuvanted) Valneva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022) 24/06/2022

[EMA recommends Valneva's COVID-19 vaccine for authorisation in the EU](/en/news/ema-recommends-valnevas-covid-19-vaccine-authorisation-eu) 23/06/2022

[EMA starts rolling review of Valneva's COVID-19 vaccine (VLA2001)](/en/news/ema-starts-rolling-review-valnevas-covid-19-vaccine-vla2001) 02/12/2021

#### More information on COVID-19 Vaccine (inactivated, adjuvanted) Valneva

- [EMEA-003077-PIP01-21 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-003077-pip01-21)
- [id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe - post-authorisation study](https://catalogues.ema.europa.eu/study/49374)

**This page was last updated on** 01/12/2023

## Share this page

[Back to top](#main-content)